Figure 3: Serelaxin Reduces Coronary Perivascular Fibrosis and Increases Left Ventricular Capillary Density in the Angiotensin II/L-NG-Nitroarginine Methyl Ester Model
2019-06-11T07:04:43Z (GMT) by
Left ventricular (LV) histology in the Acute:on-treatment group (day 9, n = 6 per group) and Chronic:post-treatment group (day 28, n = 5 per group) in angiotensin II (AngII)/L-NG-nitroarginine methyl ester (L-NAME)–treated mice. (A) Representative and summary data of perivascular fibrosis from picrosirius red–stained LV sections. Scale bars represent 1 μm. (B) Representative and summary data of capillary density from CD31 staining. Black arrows denote examples of CD31-positive capillaries. Scale bars represent 0.3 μm. Connected single bars over days 9 and 28 indicate analysis of main effects of time factor for vehicle and serelaxin in combination. *p < 0.01 treatment within day; †p < 0.001 for main effects of time factor, day 9 versus day 28; ‡p = 0.009 for main effects of treatment factor serelaxin versus vehicle. Two-factor analysis of variance with Tukey post hoc test.